Canadian Contribution to NCI Intergroup Program
Canadian Contribution to NCI Intergroup Program
批准号:
7687541
负责人:
Ralph Meyer
金额:
$134.44万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-09-30 至 2011-07-31
关键词:
AdultAmericanAwardCanadaCancer Research ProjectCancer Therapy Evaluation ProgramClinical TrialsClinical Trials Cooperative GroupCollaborationsCommitCountryData QualityDevelopmentEffectiveness of InterventionsEnrollmentEnsureEvaluationFundingFunding AgencyGoalsGrantGroup StructureGrowthHuman ResourcesInstitutionInternationalLeadershipMalignant NeoplasmsMedicalMethodologyMissionModalityMolecular BiologyNational Cancer Institute of CanadaNational Cancer Institute of Canada Clinical Trials GroupOncology GroupOntarioPatient CarePatientsPeer ReviewPhase III Clinical TrialsPlayProductivityQuality of lifeRandomizedRelative (related person)ReportingResearchResearch PersonnelResourcesRoleSiteSite VisitSocietiesStructureSystemTravelUnited StatesUniversitiesUpper armanticancer researchbasecancer therapycancer typecostdata managementdesignhealth economicsimprovedmeetingspreventprogramssoundtumorworking group
中文摘要
描述(由申请人提供):
加拿大国家癌症研究所临床试验小组(NCIC CTG)是总部设在加拿大的唯一一个拥有全国成员资格的成人肿瘤学合作小组,致力于评估不同类型癌症的所有治疗方式。该组织成立于1980年,由加拿大国家癌症研究所提供资金,该研究所是加拿大癌症协会(一个慈善组织)的研究机构。自1980年以来,NCIC CTG在其范围、成员和临床试验活动方面经历了实质性的增长。这一增长包括NCIC CTG与NCI/CTEP资助的美国合作小组合作,在美国进行的大型随机对照(第三阶段)临床试验的领导。此外,NCIC CTG是将加拿大患者纳入这些总部设在美国的组织领导的临床试验的主要机制。这笔赠款的目的是支持这些合作活动,提高加拿大和美国调查人员的生产率,并为两国的患者提供好处。NCIC CTG的使命是证明预防癌症发展或改善对癌症患者的护理的干预措施的有效性和相对有效性。这项任务的目标是将我们的临床试验建立在对分子生物学的合理理解的基础上,并在这些试验中包括相关的生物学问题,以及评估与患者和社会相关的终点,如生活质量和卫生经济学分析。要实现这一目标,需要国际合作。这笔赠款的具体目标是让NCIC CTG与NCI/CTEP和美国的小组合作,包括通过临床试验工作组报告中概述的原则,在NCIC CTG的领导下开发新的组间试验,确保更快地产生由美国小组领导的试验,通过评估更多的终点来提高这些试验的科学含量,并促进对临床试验方法学和分析的新理解。所要求的支持是为每个患者的应计费用和NCIC CTG中心办公室内的人员提供资金,以便该组织能够在加拿大有效地开发、激活和进行对我们在美国的合作者重要的试验。
英文摘要
DESCRIPTION (Provided by applicant):
The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) is the only adult cooperative oncology group based in Canada that has a national membership and is committed to assessing all modalities of therapy across the spectrum of different types of cancer. The Group was founded in 1980 through funding provided by the National Cancer Institute of Canada, which is the research arm of the Canadian Cancer Society (a charitable organization). Since 1980, the NCIC CTG has undergone substantial growth in its scope, membership, and clinical trials activities. This growth has included leadership by the NCIC CTG of large randomized controlled (phase III) clinical trials conducted in the United States in collaboration with the US-based cooperative groups that are funded by NCI/CTEP. In addition, the NCIC CTG is a principal mechanism by which Canadian patients are included in clinical trials led by these US-based groups. The purpose of this grant is to support these collaborative activities, which enhance the productivity of investigators in Canada and the US, and provide benefits to patients from both countries. The mission of the NCIC CTG is to demonstrate the efficacy and to assess the relative effectiveness of interventions that will prevent the development of cancer or will improve the care of patients who develop cancer. Goals included within this mission are to base our clinical trials on sound understandings of molecular biology and to include correlative biologic questions within these trials, as well as to evaluate endpoints that are relevant to patients and society, such as quality of life and analyses of health economics. To meet this goal requires international collaboration. The specific objectives of this grant are for NCIC CTG to collaborate with NCI/CTEP and US-based groups, including through the principles outlined in the Report of the Clinical Trials Working Group, to develop new Intergroup trials under NCIC CTG leadership and to ensure more rapid accrual to trials led by US-based groups, to enhance the scientific content of these trials through evaluation of additional endpoints and to contribute to new understandings of clinical trial methodology and analysis. The support requested is to provide funding for per-patient accrual and for personnel within the Central Office of the NCIC CTG in order that the organization can efficiently develop, activate and conduct in Canada trials that of importance to our collaborators in the United States.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Canada Clinical Trials Group Contribution to NCI Program
-
批准号:7497380
-
项目类别:
-
资助金额:$30.0万
-
财政年份:1998
-
负责人:Ralph Meyer
-
依托单位:
Canadian Contribution to NCI Intergroup Program
-
批准号:8322203
-
项目类别:
-
资助金额:$35.18万
-
财政年份:1998
-
负责人:Ralph Meyer
-
依托单位:
Canadian Contribution to NCI Intergroup Program
-
批准号:7937923
-
项目类别:
-
资助金额:$0.0万
-
财政年份:1998
-
负责人:Ralph Meyer
-
依托单位:
Canada Clinical Trials Group Contribution to NCI Program
-
批准号:7286298
-
项目类别:
-
资助金额:$132.19万
-
财政年份:1998
-
负责人:Ralph Meyer
-
依托单位:
Canadian Contribution to NCI Intergroup Program
-
批准号:7505564
-
项目类别:
-
资助金额:$149.57万
-
财政年份:1998
-
负责人:Ralph Meyer
-
依托单位:
Canadian Contribution to NCI Intergroup Program
-
批准号:8538120
-
项目类别:
-
资助金额:$139.07万
-
财政年份:1998
-
负责人:Ralph Meyer
-
依托单位:
海外基金